Condition
Locally Advanced or Metastatic Malignant Solid Tumors
Total Trials
3
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 2 (1)
Trial Status
Recruiting1
Terminated1
Active Not Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07287995Phase 1RecruitingPrimary
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
NCT04225117Phase 2Active Not RecruitingPrimary
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
NCT05326035Phase 1TerminatedPrimary
A Study of WJ05129 in Advanced Malignant Solid Tumors
Showing all 3 trials